AU2020286003B2 - Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof - Google Patents

Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof Download PDF

Info

Publication number
AU2020286003B2
AU2020286003B2 AU2020286003A AU2020286003A AU2020286003B2 AU 2020286003 B2 AU2020286003 B2 AU 2020286003B2 AU 2020286003 A AU2020286003 A AU 2020286003A AU 2020286003 A AU2020286003 A AU 2020286003A AU 2020286003 B2 AU2020286003 B2 AU 2020286003B2
Authority
AU
Australia
Prior art keywords
salt
disorder
formula
disease
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020286003A
Other languages
English (en)
Other versions
AU2020286003A1 (en
Inventor
Inese Reine
Clas Sonesson
Joakim Mihkel Tedroff
Ross Nicholas Waters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Irl 790 AB
Original Assignee
Irl 790 AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irl 790 AB filed Critical Irl 790 AB
Publication of AU2020286003A1 publication Critical patent/AU2020286003A1/en
Application granted granted Critical
Publication of AU2020286003B2 publication Critical patent/AU2020286003B2/en
Assigned to IRL 790 AB reassignment IRL 790 AB Request for Assignment Assignors: INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020286003A 2019-05-24 2020-05-20 Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof Active AU2020286003B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19176514 2019-05-24
EP19176514.8 2019-05-24
EP20166361 2020-03-27
EP20166361.4 2020-03-27
PCT/EP2020/064046 WO2020239568A1 (en) 2019-05-24 2020-05-20 Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof

Publications (2)

Publication Number Publication Date
AU2020286003A1 AU2020286003A1 (en) 2021-12-02
AU2020286003B2 true AU2020286003B2 (en) 2025-04-24

Family

ID=70682855

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020286003A Active AU2020286003B2 (en) 2019-05-24 2020-05-20 Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof

Country Status (21)

Country Link
US (2) US12275694B2 (enExample)
EP (2) EP3976581B1 (enExample)
JP (1) JP7623958B2 (enExample)
KR (1) KR102892833B1 (enExample)
CN (1) CN113853369B (enExample)
AU (1) AU2020286003B2 (enExample)
BR (1) BR112021023563A2 (enExample)
CA (1) CA3140805A1 (enExample)
CL (1) CL2021003115A1 (enExample)
CO (1) CO2021016556A2 (enExample)
DK (1) DK3976581T3 (enExample)
ES (2) ES2970361T3 (enExample)
FI (1) FI3976581T3 (enExample)
IL (1) IL288271B2 (enExample)
JO (1) JOP20210312A1 (enExample)
MX (1) MX2021014271A (enExample)
PH (1) PH12021552844A1 (enExample)
PL (1) PL3976581T3 (enExample)
PT (1) PT3976581T (enExample)
SG (1) SG11202112165QA (enExample)
WO (1) WO2020239568A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12275694B2 (en) 2019-05-24 2025-04-15 Irl 790 Ab Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof
JP7688690B2 (ja) 2020-07-28 2025-06-04 スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド ピリミジン系化合物の塩、結晶形およびその調製方法
JP2023548429A (ja) * 2020-11-10 2023-11-16 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー パーキンソン病、特にｌ－ｄｏｐａ誘発性ジスキネジアのための医薬品に対する感作の予防または軽減における使用のための［２－（３－フルオロ－５－メタンスルホニルフェノキシ）エチル］（プロピル）アミン（メスドペタム）
WO2024042540A1 (en) * 2022-08-24 2024-02-29 Alkem Laboratories Limited Mesdopetam compositions
CA3268423A1 (en) 2022-09-21 2024-03-28 Assia Chemical Industries Ltd. Solid state forms of mesdopetam and salts thereof
GB202312055D0 (en) 2023-08-07 2023-09-20 Ipsen Biopharm Ltd Pharmaceutical compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143337A1 (en) * 2011-04-19 2012-10-26 Neurosearch A/S Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51123821A (en) 1975-04-18 1976-10-28 Nippon Kayaku Co Ltd An algicide and protective agent
US4128574A (en) * 1976-10-04 1978-12-05 General Electric Company Method for making organic polycarboxylic acids
GB8823405D0 (en) 1988-10-05 1988-11-09 Erba Carlo Spa Aryloxy-arythio-heteraryloxy-heteroarylthio-alkenylene derivatives of amines
ES2169102T3 (es) 1994-10-14 2002-07-01 Merck Patent Gmbh (r)-(-)-2-(5-(4-fluorfenil)-3-piridilmetilaminometil)-cromano como agente activo sobre el sistema nervioso central.
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
DOP2001000189A (es) 2000-06-30 2002-03-30 Pfizer Prod Inc Benzofenonas y sulfonas como inhibidores de la captación de glicina
JP2006193494A (ja) 2005-01-17 2006-07-27 Dainippon Ink & Chem Inc ４級アンモニウム系化合物を有効成分とする心臓疾患治療剤
CN101203511A (zh) 2005-06-23 2008-06-18 阿斯利康(瑞典)有限公司 作为神经激肽受体拮抗剂用于治疗胃肠疾病的新氮杂环丁烷衍生物
WO2007063789A1 (ja) 2005-11-29 2007-06-07 Kissei Pharmaceutical Co., Ltd. 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途
WO2007072041A1 (en) 2005-12-23 2007-06-28 Astex Therapeutics Limited Therapeutic compounds
AU2007218086A1 (en) * 2006-02-15 2007-08-30 M's Science Corporation Piperazine derivatives
CA2687721A1 (en) * 2007-06-08 2008-12-18 Arena Pharmaceuticals, Inc. Crystalline forms of (r)-1-{2-[4'-(3-methoxy-propane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
JP2011519839A (ja) 2008-04-29 2011-07-14 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ ドーパミン神経伝達のモジュレーター
WO2009133110A1 (en) 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
MX2010011724A (es) 2008-04-29 2010-11-30 Nsab Af Neurosearch Sweden Ab Moduladores de neurotransmision de dopamina.
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
MX391727B (es) 2016-02-08 2025-03-21 Merck Patent Gmbh Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfonil-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-metilbenzoil)guanidina.
EP3625213B1 (en) 2017-05-19 2023-03-08 Integrative Research Laboratories Sweden AB (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine fumarate, a process for its preparation and uses thereof
SG11202000833YA (en) * 2017-08-07 2020-02-27 Suven Life Sciences Ltd Fluoropiperidine compounds as pure 5-ht6 receptor antagonists
WO2020110128A1 (en) 2018-11-29 2020-06-04 Prilenia Neurotherapeutics Ltd. Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia
US12275694B2 (en) 2019-05-24 2025-04-15 Irl 790 Ab Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143337A1 (en) * 2011-04-19 2012-10-26 Neurosearch A/S Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission

Also Published As

Publication number Publication date
WO2020239568A1 (en) 2020-12-03
JP7623958B2 (ja) 2025-01-29
EP3976581A1 (en) 2022-04-06
MX2021014271A (es) 2022-01-06
KR20220011638A (ko) 2022-01-28
BR112021023563A2 (pt) 2022-01-04
US20240343687A2 (en) 2024-10-17
EP4292653A3 (en) 2024-04-24
US20250243155A1 (en) 2025-07-31
EP4292653A2 (en) 2023-12-20
JOP20210312A1 (ar) 2023-01-30
CO2021016556A2 (es) 2022-01-17
IL288271A (en) 2022-01-01
ES3072819T3 (en) 2026-07-06
PL3976581T3 (pl) 2024-07-01
KR102892833B1 (ko) 2025-12-02
CN113853369A (zh) 2021-12-28
EP3976581B1 (en) 2023-11-22
IL288271B2 (en) 2025-02-01
IL288271B1 (en) 2024-10-01
CN113853369B (zh) 2025-08-22
PH12021552844A1 (en) 2022-10-17
EP4292653B1 (en) 2026-03-18
US12275694B2 (en) 2025-04-15
CA3140805A1 (en) 2020-12-03
ES2970361T3 (es) 2024-05-28
DK3976581T3 (da) 2024-01-22
SG11202112165QA (en) 2021-12-30
JP2022533433A (ja) 2022-07-22
PT3976581T (pt) 2024-02-08
US20220267262A1 (en) 2022-08-25
AU2020286003A1 (en) 2021-12-02
CL2021003115A1 (es) 2022-09-30
FI3976581T3 (fi) 2024-01-31

Similar Documents

Publication Publication Date Title
US20250243155A1 (en) Pharmaceutically Acceptable Salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and Uses Thereof
US20240400505A1 (en) (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof
AU2013291617B2 (en) Carbamate/urea derivatives
US20240148674A1 (en) Pharmaceutically acceptable salts of mesdopetam and uses thereof
HK40063249A (en) Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof
EA047399B1 (ru) Фармацевтически приемлемые соли [2-(3-фтор-5-метансульфонилфенокси)этил](пропил)амина и их применение
HK40063249B (en) Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof
CA3064136C (en) (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof
WO2025008504A1 (en) Pharmaceutically acceptable salts of 3-(2,3-difluorophenoxy)azetidine and uses thereof
US20110130389A1 (en) Fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate, crystalline forms thereof, preparation thereof and therapeutic use thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: IRL 790 AB

Free format text: FORMER APPLICANT(S): INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB

FGA Letters patent sealed or granted (standard patent)